Birth control

The Prelude Network Announces 10 of its Clinics Have Been Named America's Best Fertility Clinics

Retrieved on: 
Thursday, April 18, 2024
Fertility, Infertility, CDC, Science, Patient, Physician, Patient satisfaction, Prelude, Reproductive medicine, Birth control

HOUSTON, April 18, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest provider of comprehensive fertility services and clinics across North America, announces today nine of its clinics have been named an America's Best Fertility Clinic in 2024.

Key Points: 
  • Presented by Newsweek, America's Best Fertility Clinics 2024 ranks the top 125 fertility clinics nationwide based on surveys, quality metrics, accreditation data, and patient satisfaction
    HOUSTON, April 18, 2024 /PRNewswire/ -- The Prelude Network ® (Prelude), the largest provider of comprehensive fertility services and clinics across North America, announces today nine of its clinics have been named an America's Best Fertility Clinic in 2024.
  • Presented by Newsweek, the America's Best Fertility Clinics 2024 ranking lists the top 125 fertility clinics as defined by the CDC (Centers for Disease Control and Prevention).
  • With global researcher Statista, over 3,000 physicians and other fertility medicine professionals were surveyed, including reproductive endocrinologists, infertility specialists, obstetricians/gynecologists working in and referring patients to fertility clinics, as well as other medical professionals (e.g., registered nurses, laboratory assistants) and fertility clinic administrators/managers working in fertility clinics, to assess confidence in their assessment of the fertility clinics, which was used to determine individual weights for the recommendations.
  • Other criteria that for America's Best Fertility Clinics 2024 award include:
    Quality Metrics: Assisted Reproductive Technology metrics with a focus on indicators relevant to fertility clinics published by CDC were analyzed.

Rosy Debuts New Content Focused on Menopause and Migraine Education

Retrieved on: 
Thursday, April 18, 2024
Physician, Webby, PCOS, Woman, Health, MD, Endometriosis, Webby Awards, Migraine, Female, Sensation, Patient, Diagnosis, OB, Libido, Personal lubricant, Quality of life, Menopause, Knowledge, Disability, Birth control

DALLAS, April 18, 2024 /PRNewswire-PRWeb/ -- Rosy, the Webby Award winning app-based platform that addresses common health concerns for women throughout their lifespans, announces an expanded focus beyond sexual wellness. Through its new sponsorship from Pfizer, one of the world's premier biopharmaceutical companies, Rosy will provide women in the U.S. with free evidence-based resources, rolled out in two phases. The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.

Key Points: 
  • The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.
  • When signing up for Rosy, each user takes a comprehensive Wellness Quiz, allowing Rosy to personalize an evidence-based, CBT-informed program with their unique concerns and priorities in mind.
  • While initially focused on sexual wellness, Rosy has expanded to include a wider range of women's health concerns, including endometriosis, PCOS, and more.
  • Physicians, providers, and hospital systems interested in recommending Rosy to their female patients are welcome to email [email protected] .

The Mama Glow Foundation Receives Grant to Develop Restorative Justice Breastfeeding Education Program for Doulas

Retrieved on: 
Thursday, April 18, 2024
Education, Safety, Maternal health, Caregiver, Workforce, Mother, Lactation, Birth control

BROOKLYN, N.Y., April 18, 2024 /PRNewswire/ -- The First Foods Justice Breastfeeding Certification Program for Doulas, is centered on reclaiming breastfeeding education and bringing lactation support to communities most impacted by low breastfeeding rates. The program was first announced at the third annual Doula Expo by Mama Glow last year and holds a vision of restorative justice.

Key Points: 
  • The Maternal Health organization, Mama Glow Foundation, debuts a new national training program rooted in breastfeeding education and restorative justice.
  • BROOKLYN, N.Y., April 18, 2024 /PRNewswire/ -- The First Foods Justice Breastfeeding Certification Program for Doulas, is centered on reclaiming breastfeeding education and bringing lactation support to communities most impacted by low breastfeeding rates.
  • The program was first announced at the third annual Doula Expo by Mama Glow last year and holds a vision of restorative justice.
  • The maternal health organization, Mama Glow Foundation is unveiling a historic effort to address the disparities in Black breastfeeding rates in the USA.

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

Retrieved on: 
Thursday, April 18, 2024
FDA, Patient, Lactic acid, Orange, Pregnancy, Woman, OTCQB, Hormone, Orange Book, Citric acid, Birth, Patent, SAN, Birth control

SAN DIEGO, April 18, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

Key Points: 
  • This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
  • The allowed claims cover methods of contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.
  • The patent, when issued, will be Evofem's fifth patent for Phexxi in the United States.
  • "This patent allowance attests to the innovation Phexxi brings to contraception and a woman's ability to protect herself from unintended pregnancy with no hormones."

Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)

Retrieved on: 
Thursday, April 18, 2024
FDA, Risk, Social services, Urinary tract infection, Health Canada, Infant, Deliberation, European, Access, Physician, The Committee, Committee, Hospital, Parent, Sanofi, Infection, RSV, Birth control

TORONTO, April 18, 2024 /CNW/ - Quebec's National Institute of Excellence in Health and Social Services (INESSS) recommends BEYFORTUS® to be used for the prevention of RSV lower respiratory tract disease (LRTD) in all neonates and infants aged 8 months and younger.

Key Points: 
  • TORONTO, April 18, 2024 /CNW/ - Quebec's National Institute of Excellence in Health and Social Services (INESSS) recommends BEYFORTUS® to be used for the prevention of RSV lower respiratory tract disease (LRTD) in all neonates and infants aged 8 months and younger.
  • I believe every baby deserves to be protected against RSV and this recommendation for BEYFORTUS® marks an important milestone towards achieving that goal in Quebec.
  • Now is the time to protect all infants against this devastating illness."
  • Sanofi is working with Quebec provincial authorities to make BEYFORTUS® available to a broad cohort of infants for the 2024-25 RSV season.

Beli Introduces Innovative Preconception Boost: A New Step Toward Optimizing Fertility Before Pregnancy

Retrieved on: 
Thursday, April 18, 2024
PCOS, PMS, Pregnancy, Health, Thought, Fertility, Water, Science, Nutrient, Multimedia, Ovulation, Overalls, Knowledge, Birth control

KIRKLAND, Wash., April 18, 2024 /PRNewswire-PRWeb/ -- Targeted nutrient support for Hormonal Balance, Egg Quality, Cycle Regularity and More in One Innovative Supplement

Key Points: 
  • Beli is excited to announce the launch of its latest innovation, the Beli Preconception Boost for Women.
  • Beli is excited to announce the launch of its latest innovation, the Beli Preconception Boost for Women.
  • "Beli stands at the forefront of fertility and preconception health with the launch of this supplement," added Davis.
  • The Preconception Boost for Women is now available, marking a new era in fertility and preconception care.

Maven Clinic Expands Award-Winning Fertility & Family Building Solution with Focus on Natural Conception

Retrieved on: 
Wednesday, April 17, 2024
NICU, ROI, Fertility, Pregnancy, Woman, TTC, Male, Kate Ryder, IVF, MMB, Family, Mental health, Patient, Health, Birth control

NEW YORK, April 17, 2024 /PRNewswire/ -- Maven Clinic, the world's largest virtual clinic for women's and family health, today announced that it has expanded its award-winning Fertility & Family Building program. With 86% of women not receiving preconception care from their family physician or OB-GYN, Maven's Trying-To-Conceive (TTC) health coaching program supports people who may be struggling and want to get pregnant without IVF. Further product enhancements also include the Maven Managed Benefit platform, which combines virtual care management with custom fertility benefit design and carve-out administration, as well as an expansion of its reproductive urology provider network for male fertility support. 

Key Points: 
  • "Maven is making sure every family can access the shortest pathway to having a healthy baby," said Maven Clinic CEO and founder Kate Ryder.
  • Across all Maven Fertility & Family Building program members, 30% of members achieve pregnancy without the need for assisted reproductive technology.
  • With Maven Managed Benefit (MMB), Maven Clinic is the only family building platform where care and coverage are seamlessly integrated through best-in-class technology.
  • Since 2018, Maven Clinic has provided efficient reimbursement for fertility and family building services through its innovative payment platform, Maven Wallet.

75% OF WOMEN AGES 18-59 EXPERIENCED MULTIPLE PELVIC HEALTH ISSUES IN THE PAST YEAR ACCORDING TO A NEW STUDY BY ORIGIN AND IPSOS

Retrieved on: 
Wednesday, April 17, 2024
Pelvis, News, Woman, Urinary incontinence, Constipation, Ipsos, Depression, Pelvic floor, Origin, PFD, Pelvic floor dysfunction, Gen, Mental health, Patient, Pelvic pain, Movement, Anxiety, Prevalence, Birth control

LOS ANGELES, April 17, 2024 /PRNewswire/ -- Origin, the leading nationwide provider of pelvic floor and women's health physical therapy, today released the "2024 Origin Pelvic Health Study," conducted by market research firm Ipsos and made possible by funding organized by Rise Together Ventures.

Key Points: 
  • LOS ANGELES, April 17, 2024 /PRNewswire/ -- Origin, the leading nationwide provider of pelvic floor and women's health physical therapy, today released the "2024 Origin Pelvic Health Study," conducted by market research firm Ipsos and made possible by funding organized by Rise Together Ventures .
  • The study reveals a hidden pelvic health crisis among women ages 18-59, not just for Gen X women, but also a shockingly high number of Millennials as young as 27.
  • Reported symptoms include bladder and bowel issues, sexual dysfunction, and pelvic pain.
  • At Origin, 9 out of 10 of patients report an improvement in pelvic floor symptoms.

World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"

Retrieved on: 
Wednesday, April 17, 2024
Haemophilia, World government, Bleeding, Woman, CSL Behring, City, WFH, NMO, Male, Parent, Friends, World Federation of Hemophilia, Novo Nordisk, Treatment, Bayer, LFB, Diagnosis, All, Coagulopathy, VWD, Therapy, Sanofi, Birth control

MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.

Key Points: 
  • MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.
  • The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders".
  • The World Federation of Hemophilia (WFH) vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, age, or where they live.
  • This April, let's celebrate our community and continue working towards a world where everyone—with hemophilia A or B, von Willebrand disease (VWD) or any other bleeding disorder—has access to diagnosis, treatment, and comprehensive care.

World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"

Retrieved on: 
Wednesday, April 17, 2024
Haemophilia, World government, Bleeding, Woman, CSL Behring, City, WFH, NMO, Male, Parent, Friends, World Federation of Hemophilia, Novo Nordisk, Treatment, Bayer, LFB, Diagnosis, All, Coagulopathy, VWD, Therapy, Sanofi, Birth control

MONTREAL, April 17, 2024 /PRNewswire/ - On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.

Key Points: 
  • MONTREAL, April 17, 2024 /PRNewswire/ - On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.
  • The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders".
  • The World Federation of Hemophilia (WFH) vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, age, or where they live.
  • This April, let's celebrate our community and continue working towards a world where everyone—with hemophilia A or B, von Willebrand disease (VWD) or any other bleeding disorder—has access to diagnosis, treatment, and comprehensive care.